List of Excipients in Branded Drug JYNNEOS

« Back to Dashboard

Last updated: October 21, 2026

JYNNEOS is a live, non-replicating MVA-BN vaccine whose commercial value is driven more by cold-chain performance, vial utilization, manufacturing scale, and government procurement than by conventional excipient exclusivity. Its disclosed formulation is comparatively simple: modified vaccinia Ankara-Bavarian Nordic, tromethamine, sodium chloride, and water for injection, with trace process-related residues including antibiotics, egg protein, and benzonase-related materials. The strongest excipient opportunities are improved thermostability, multidose presentation, intradermal-use compatibility, and manufacturing support rather than a direct substitution for the approved product. [1]

JYNNEOS Excipient Strategy, Formulation Patents, and Commercial Opportunities

What is JYNNEOS and how is it formulated?

JYNNEOS is Bavarian Nordic’s MVA-BN vaccine for prevention of smallpox and mpox in adults at increased risk. The U.S. Food and Drug Administration approved the product in 2019 under biologics license application BLA 125678. It is a replication-deficient live-virus vaccine administered as a two-dose series by subcutaneous injection. [1]

The labeled formulation per 0.5 mL dose contains:

Component	Function or relevance
MVA-BN virus	Active immunizing component
Tromethamine, also called Tris	Buffer and pH control
Sodium chloride	Tonicity adjustment
Water for injection	Vehicle
Trace residuals	May include gentamicin, ciprofloxacin, chicken-protein residues, and benzonase-related process residues

JYNNEOS does not contain a preservative in the labeled formulation. The FDA label identifies approximately 10 mg of tromethamine and 4 mg of sodium chloride per 0.5 mL dose, with the active-virus content expressed as an infectious-unit range rather than a fixed mass dose. [1]

The formulation strategy reflects the manufacturing requirements of a live viral vaccine. The excipient system must preserve infectivity, control pH and osmolality, limit aggregation, and remain compatible with the MVA-BN production and purification process.

Which excipients are most important?

Tromethamine is the principal buffering excipient. It helps control pH during storage and administration, but its concentration, buffer capacity, and interaction with viral particles must be evaluated against infectivity retention.

Sodium chloride provides tonicity control. Its concentration also affects protein and particle interactions, freeze-thaw behavior, and the risk of aggregation.

Water for injection is the vehicle. Since JYNNEOS is supplied as a liquid-frozen vaccine, water quality and container-closure integrity are important to product stability.

The main formulation constraint is that an excipient must improve stability without reducing MVA-BN infectivity. Conventional protein-stabilization approaches cannot be assumed to work for a live poxvirus vaccine.

What are the storage and cold-chain requirements for JYNNEOS?

JYNNEOS is supplied as a frozen liquid. The U.S. prescribing information specifies storage at -25°C to -15°C. After thawing, the vaccine may be stored at 2°C to 8°C for the labeled period, provided it remains within the approved handling conditions. [1]

The cold-chain profile creates a commercial opportunity for excipient and presentation improvements.

Commercial problem	Potential formulation response	Business value
Frozen distribution limits deployment	Improve liquid stability at refrigerated temperature	Wider use in clinics and public-health programs
Freeze-thaw exposure can reduce potency	Add compatible stabilizers or optimize buffer strength	Lower wastage and shipping risk
Single-dose vials increase packaging and administration costs	Develop a validated multidose presentation	Lower per-dose delivery cost
Intradermal dosing requires smaller volumes	Validate low-volume dose uniformity and device compatibility	Increase doses available from existing stock
Emergency stockpiles require long storage	Improve long-term potency retention	Reduce replacement frequency
International distribution can be difficult	Increase temperature tolerance	Support non-U.S. procurement and outbreak response

An improved formulation would need to preserve viral infectivity, maintain sterility, avoid unacceptable reactogenicity, and remain compatible with the existing vial, stopper, needle, and administration process.

What formulation patents could protect JYNNEOS improvements?

The core JYNNEOS composition is associated with Bavarian Nordic’s MVA-BN platform and regulatory product approvals. A competitor would face substantial biological, manufacturing, and regulatory barriers even if the basic excipients are generic.

Potentially protectable subject matter includes:

1. Specific stabilizer combinations that preserve MVA-BN infectivity.
2. Buffer systems that maintain potency during freeze-thaw cycles.
3. Liquid formulations stable at 2°C to 8°C.
4. Lyophilized or spray-dried MVA-BN compositions.
5. Multidose formulations with validated antimicrobial protection.
6. Container-closure systems that reduce adsorption or extractables.
7. Low-volume formulations for intradermal delivery.
8. Manufacturing and purification methods that improve viral yield or consistency.
9. Defined impurity limits for residual antibiotics, host-cell proteins, DNA, or process enzymes.
10. Device combinations for intradermal or other dose-sparing administration.

A useful patent strategy would combine composition claims with use, process, and container-closure claims. Composition claims alone may be vulnerable if the same buffer and salt system appear in earlier live-vaccine or poxvirus literature.

How strong is the excipient patent estate for JYNNEOS?

The excipient estate appears less likely to be the primary exclusivity barrier than the MVA-BN platform, manufacturing know-how, clinical data, regulatory approvals, and government procurement position. Tromethamine, sodium chloride, and water for injection are established pharmaceutical excipients with limited standalone patent value.

The strongest potential formulation claims would require a defined technical effect, such as:

• statistically demonstrated retention of infectious titer;
• stability after repeated freeze-thaw cycles;
• improved refrigerated shelf life;
• reduced aggregation or particle-size change;
• improved intradermal dose recovery;
• preserved potency in a multidose container; or
• reduced adsorption to the vial or syringe.

A patent directed only to using standard concentrations of Tris and sodium chloride would face substantial novelty and obviousness risk. A claim tied to a specific MVA-BN infectivity range, excipient ratio, storage condition, and stability result would be more defensible.

Is JYNNEOS listed in the Orange Book?

No. JYNNEOS is a biologic licensed under a BLA, not a conventional small-molecule drug approved under an NDA. The relevant FDA reference framework is the Purple Book and the biologics licensing system rather than the Orange Book patent-listing process. [2]

This distinction affects generic-entry analysis. A conventional ANDA Paragraph IV challenge is not the standard pathway for JYNNEOS. A competitor would need to pursue an applicable biologics pathway, most likely a standalone BLA for a distinct vaccine product unless an authorized biosimilar or interchangeable pathway were legally and scientifically suitable.

When does JYNNEOS lose exclusivity?

JYNNEOS does not have a single Orange Book patent expiration date that determines generic entry. Its market protection has several components:

Protection layer	Relevance to JYNNEOS
BLA regulatory exclusivity	FDA biologic exclusivity applies under the Public Health Service Act framework
MVA-BN platform patents	May cover virus generation, production, composition, or use
Manufacturing know-how	Includes cell culture, infection, purification, and potency-control methods
Formulation patents	May cover stability, storage, presentation, or administration
Government procurement	Can sustain commercial access independent of ordinary retail competition
Clinical and regulatory data	Raises development cost for competing vaccines
Supply agreements	May restrict practical access to public-health markets

The FDA approval date was September 24, 2019. The regulatory exclusivity period should be analyzed separately from any patent term and should not be treated as a conventional small-molecule five-year period. [1, 3]

A competitor could still develop a separate smallpox or mpox vaccine before all platform patents expire if it avoids protected claims and generates its own clinical and manufacturing package. That process would be costly and time-intensive.

Are there Paragraph IV challenges or generic launch risks?

There is no conventional Paragraph IV pathway for JYNNEOS because the product is a biologic. Publicly visible generic litigation risk is therefore lower than for a small-molecule product, but the absence of an ANDA Paragraph IV challenge does not mean the product lacks competitive risk.

The principal entry scenarios are:

• a new BLA for a competing smallpox or mpox vaccine;
• an MVA-based vaccine developed by another manufacturer;
• a non-replicating poxvirus vaccine using a different platform;
• a government-sponsored vaccine program;
• an authorized or interchangeable biological product, if legally and scientifically applicable;
• a licensed technology or regional manufacturing partnership.

The development risk is high because the competing product must demonstrate acceptable safety, immunogenicity, potency, consistency, and manufacturing control. A competitor also needs access to outbreak-response procurement channels.

What formulation opportunities exist for pharmaceutical excipient companies?

Thermostable JYNNEOS presentation

A formulation stable for longer periods at 2°C to 8°C would have the clearest commercial value. It could reduce dependence on frozen transport and simplify deployment in clinics, pharmacies, military settings, and international public-health programs.

The development target should be measured by retained infectious titer, not merely appearance or total viral particle count.

Lyophilized MVA-BN vaccine

A freeze-dried presentation could improve storage flexibility, but lyophilization introduces reconstitution risk, vial-processing complexity, and possible loss of infectivity. The excipient system would likely require a carefully selected protectant and bulking agent. Any such product would need new stability, reconstitution, container-closure, and clinical comparability work.

Multidose vial technology

A multidose vial could reduce packaging and administration costs. It would require control of microbial contamination, dose uniformity, in-use stability, stopper puncture performance, and preservative compatibility. The absence of a preservative in the approved product makes this opportunity technically attractive but clinically and regulatorily demanding.

Intradermal delivery

FDA authorized intradermal administration of JYNNEOS in 2022 at a reduced volume during a public-health emergency. The approach can increase the number of administered doses from available supply, but it places greater demands on dose accuracy, device performance, and administration training. [4]

Commercial opportunities include low-dead-volume syringes, microneedle systems, validated intradermal devices, and presentations optimized for 0.1 mL dosing. These opportunities are combination-product or device opportunities as much as excipient opportunities.

Residual impurity reduction

JYNNEOS contains trace manufacturing residues identified in labeling. Improved purification could reduce antibiotic or protein residues, simplify allergy-related risk management, and support broader global procurement. The value depends on whether the change improves clinical positioning or removes a regulatory obstacle in a target market.

How does JYNNEOS compare with competing mpox vaccines?

JYNNEOS is differentiated by its non-replicating MVA-BN platform and its use in people for whom replication-competent vaccinia vaccines may be unsuitable. ACAM2000, manufactured by Emergent BioSolutions, is a replication-competent vaccinia vaccine with a different safety and administration profile. [5]

Attribute	JYNNEOS	ACAM2000
Platform	Non-replicating MVA-BN	Replication-competent vaccinia
Administration	Two-dose series; SC label, ID emergency use	Scarification
Excipient opportunity	Stability, multidose use, low-volume delivery	Reconstitution, scarification delivery, stability
Safety positioning	More suitable for certain immunocompromised populations	More significant vaccinia-related safety restrictions
Commercial buyer	Government stockpiles, public-health agencies, clinics	Primarily government and specialized public-health channels
Biosimilar risk	Low near-term conventional biosimilar risk	Low near-term conventional biosimilar risk

JYNNEOS has a stronger formulation and delivery opportunity because its liquid-frozen presentation and intradermal use create clear operational constraints.

What licensing and manufacturing opportunities exist?

Bavarian Nordic’s commercial position is based on the MVA-BN platform, regulatory approvals, manufacturing capacity, and government relationships. The most realistic licensing opportunities for outside companies are likely to involve:

• regional fill-finish;
• cold-chain and distribution services;
• intradermal delivery devices;
• excipient or formulation development;
• contract manufacturing;
• analytical methods for infectious titer and potency;
• supply of specialized single-use manufacturing components;
• regional stockpile agreements.

A third party seeking to commercialize an MVA-BN-based product would need to assess platform rights, manufacturing licenses, territorial rights, government-use provisions, and freedom to operate across the United States, European Union, Canada, and outbreak-prone markets.

Manufacturing IP may be more commercially important than excipient patents. Live-virus production requires validated cell substrates, controlled infection conditions, purification, aseptic filling, potency assays, and release specifications. Those capabilities create barriers that are difficult to reproduce through ordinary formulation substitution.

What is the revenue exposure and market outlook for JYNNEOS?

JYNNEOS revenue is exposed to government procurement cycles, declared outbreaks, stockpile replenishment, and vaccination policy. Demand can rise sharply during mpox outbreaks and fall when emergency procurement ends.

The principal revenue channels are:

• U.S. Strategic National Stockpile purchases;
• federal and state public-health orders;
• international government procurement;
• outbreak-response contracts;
• occupational or travel-related vaccination;
• replenishment of expiring stock.

Excipient suppliers should evaluate the product as a public-health manufacturing platform rather than a conventional recurring retail vaccine. The highest-value commercial proposition is a measurable reduction in delivered cost per usable dose. That can come from lower wastage, improved temperature tolerance, increased doses per vial, faster filling, or more efficient intradermal administration.

Key Takeaways

• JYNNEOS uses a relatively simple labeled excipient system based on tromethamine, sodium chloride, and water for injection.
• The product is a BLA-regulated biologic, so Orange Book listings and Paragraph IV litigation are not the principal competitive framework.
• JYNNEOS’s commercial protection relies on MVA-BN platform rights, manufacturing know-how, regulatory data, government procurement, and supply relationships.
• The most valuable formulation opportunities are refrigerated stability, thermostability, multidose presentation, lyophilization, and intradermal dose optimization.
• Standard excipients have limited standalone patent value. Stronger claims would require defined compositions linked to demonstrated MVA-BN potency or stability improvements.
• Competitive entry is more likely through a new BLA, platform license, or alternative vaccine technology than through a conventional generic launch.
• Manufacturing and analytical-control barriers may be more difficult to overcome than the disclosed excipient composition.

FAQs

Can JYNNEOS excipients be substituted without a new approval?

No. A change to the approved formulation would require regulatory comparability, stability, manufacturing, and potentially clinical support. The change would be assessed under the FDA’s post-approval biologics framework.

Does JYNNEOS contain an adjuvant?

The labeled JYNNEOS formulation does not identify a conventional immunologic adjuvant such as aluminum salts or a saponin system. Its immune response is generated by the MVA-BN vaccine platform.

Could a preservative be added to create a multidose JYNNEOS vial?

Potentially, but preservative compatibility with live MVA-BN, potency retention, local tolerability, container-closure performance, and microbial-control data would be required. The approved product does not contain a preservative.

Is a thermostable JYNNEOS formulation likely to receive separate patent protection?

It could, if the formulation produces a non-obvious and measurable improvement in infectious-titer retention, storage life, freeze-thaw tolerance, or administration performance. A routine buffer or salt substitution would face weaker patent prospects.

Are biosimilars a near-term threat to JYNNEOS?

The near-term threat from a conventional biosimilar is limited. The more credible competitive risks are a separate vaccine BLA, an alternative mpox vaccine platform, government-supported manufacturing, or a licensed MVA-BN product.

References

1. U.S. Food and Drug Administration. (2024). JYNNEOS (smallpox and mpox vaccine, live, non-replicating): Prescribing information.
2. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
3. U.S. Code. (2024). 42 U.S.C. § 262: Regulation of biological products.
4. U.S. Food and Drug Administration. (2022). JYNNEOS emergency use authorization for intradermal administration.
5. U.S. Food and Drug Administration. (2024). ACAM2000 smallpox vaccine: Prescribing information.